Amino acids (AAs) are biologically important nutrient compounds necessary for the survival of any cell. Of the 20 AAs, cancer cells depend on the uptake of several extracellular AAs for survival. However, which extracellular AA is indispensable for the survival of cancer cells and the molecular mechanism involved have not been fully defined. In this study, we found that the reduction of cell survival caused by glutamine (Gln) depletion is inversely correlated with the expression level of glutamine synthetase (GS) in ovarian cancer (OVC) cells. GS expression was downregulated in 45 of 316 OVC cases (14.2%). The depletion of extracellular Gln by treatment with l-asparaginase, in addition to inhibiting Gln uptake via the knockdown of a Gln transporter, led to the inhibition of cell growth in OVC cells with low expression of GS (GS low -OVC cells). Furthermore, the re-expression of GS in GS low -OVC cells induced the inhibition of tumor growth in vitro and in vivo. Thus, these findings provide novel insight into the development of an OVC therapy based on the requirement of Gln.
Introduction
Ovarian cancer (OVC) is the fifth cause of cancer-related death in women. Epithelial ovarian cancer comprises 90% of all OVCs and is classified into four histologic subtypes of serous, mucinous, endometrioid and clear cell carcinomas (1, 2) . OVC is a global problem, is typically diagnosed at a late stage and is frequently relapse (3) . Therefore, it is necessary to identify novel and efficient treatment for human epithelial ovarian cancer.
Amino acids (AAs) are biologically important nutrient compounds necessary for the survival of any cell. Of the 20 AAs, 9 essential amino acids (EAAs) cannot be synthesized endogenously and must be obtained as extracellular components. In contrast, 11 nonessential amino acids (NEAAs) can be endogenously synthesized by each corresponding enzyme (4) (5) (6) . Accumulating evidence has demonstrated that certain types of cancer cells depend on several NEAAs, including arginine, glycine, leucine, glutamine (Gln), proline and serine, for cell survival (7) (8) (9) (10) (11) (12) (13) . However, which extracellular AA is indispensable for the survival of cancer cells and the underlying molecular mechanism have not been fully defined.
On the other hand, it is known that l-asparaginase (l-asp), which is one of the most important drugs used for acute lymphoblastic leukemia (ALL) therapy, is an enzyme that catalyzes the hydrolysis of asparagine or Gln to aspartate or glutamate (Glu), respectively. The l-asp-mediated depletion of blood asparagine is the basic therapeutic concept in ALL because ALL cells cannot synthesize endogenous asparagine due to the lack of asparagine synthetase (ASNS), resulting in the dependency on extracellular asparagine uptake (14, 15) . Additionally, argininosuccinate synthetase 1 (ASS1) is a key enzyme in arginine biosynthesis and prolonged arginine starvation by exposure to pegylated arginine deiminase (ADI-PEG20) sensitive in ASS1-deficient breast cancer cells, because these cells are arginine auxotrophs, and depend on extracellular arginine uptake (11) . Thus, the absence of a biosynthetic enzyme for any of the NEAAs leads to the insufficient intracellular production of that NEAA in the tumor of each individual cancer patient. Therefore, the depletion of specific AAs is expected to be therapeutically useful for precision cancer medicine.
In this study, we found that the downregulation of glutamine synthetase (GS) expression led to the increased sensitivity to Gln depletion in OVC cells. GS expression was downregulated in a subset of primary OVC cases. The depletion of extracellular Gln by treatment with l-asp, in addition to inhibiting Gln uptake via the knockdown of a Gln transporter, led to the inhibition of cell growth in OVC cells with low expression of GS (GS low -OVC cells). These findings provide novel insight into the development of OVC therapy based on the requirement of Gln.
Materials and methods

Cell lines and cell culture
A total of 14 OVC cell lines were used in this study. The A2780, KK, KF28, MH, OVCAR-3, OVCAR-5, OVCAR-8 and SNU119 cells were maintained in RPMI 1640 medium (WAKO, Osaka, Japan); A#39 cells were maintained in DMEM/F12 medium (WAKO); CaOV3 cells were maintained in DMEM medium (WAKO); ES-2 and SK-OV-3 cells were maintained in McCoy's 5a medium (Thermo Fisher Scientific, Waltham, MA); the TOV21G cells were maintained in a 1:1 mixture of MCDB-105/M199 medium (Cell Applications, San Diego, CA/Thermo Fisher Scientific) and the RMG-1 cells were maintained in Ham's F12 medium (WAKO). Each culture medium was supplemented with 10% fetal bovine serum. The cultures were maintained at 37°C with 5% CO 2 . Of the 14 OVC cell lines used, ES-2, OVCAR-3 and SK-OV-3 were obtained from the American Type Culture Collection (ATCC, Manassas, VA); KK, KF28 and MH were from the National Defense Medical College (Saitama, Japan) (16); A2780, SNU119, A#39, CaOV3 and TOV21G were kindly provided by Dr Y.S.S. (Seoul National University, Seoul, Korea); RMG-1 cell line was kindly provided by Dr D.A. (Keio University School of Medicine, Tokyo, Japan) (17) . Once resuscitated, the cell lines were authenticated through monitoring of cell morphology.
Patients and tumor specimens
Formalin-fixed, paraffin-embedded tissue blocks of primary epithelial OVCs from 316 patients were used to construct tissue microarrays. All patients underwent surgery at the National Defense Medical College (NDMC) Hospital (Saitama, Japan) from 1986 to 2006 with a 10 year followup period starting from the initial surgery. The median follow-up period was 59.5 months (range, 1-257 months). Of the 316 patients, 114 (36.1%) died due to their cancer. The tumor histological types were classified according to the WHO criteria. The clinical stages of the disease were classified according to the 1988 International Federation of Gynecology and Obstetrics (FIGO) system. All patients provided written informed consent in a formal style before the study. This study was approved by the ethics committees of the NDMC and Tokyo Medical and Dental University (TMDU).
Antibodies and reagents
Antibodies for GS (G2781), ASNS (HPA029318), LC3B (L7543) and β-actin (A5441) were purchased from Sigma-Aldrich (St. Louis, MO). Antibodies directed against ASCT2 (#5100) were from Cell Signaling (Danvers, MA). l-Asparaginase (l-asp; LEUNASE) was purchased from Kyowa Hakko Kirin Co (Tokyo, Japan). Bafilomycin A1 (Baf.A1) was purchased from Sigma-Aldrich.
Preparation of single AA-depleted medium
Conditioned medium, a single AA-depleted medium, was prepared by adding the other 19 AAs (at a final concentration of 100 µM), excluding one AA, to AA-free RPMI 1640 medium (WAKO) supplemented with 0.1% fetal bovine serum. Alanine, aspartate, Glu, glycine, leucine, methionine, serine, tryptophan, tyrosine and valine were purchased from WAKO. Arginine, asparagine, cysteine, Gln, histidine, isoleucine, lysine, phenylalanine, proline and threonine were purchased from Peptide Institute (Osaka, Japan).
Transfection of siRNAs
Small-interfering RNAs (siRNAs) for GS (siGENOME SMARTpool; M-008228-01-0005), ASCT2 (siGENOME SMARTpool; M-007429-01-0005), a Gln transporter and a nontargeting negative control (siGENOME SMARTpool; D-001206-14-05) were obtained from Thermo Fisher Scientific. The cells were transfected with each siRNA at 20 nM using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
Plasmid construction
The PCR product containing the coding region of GS was inserted into a pCMV-3Tag-1A (Flag tagged) expression vector (Stratagene, San Diego, CA). Short hairpin RNA (shRNA) oligonucleotides for GS gene (target sequence: 5′-CCCTAAACCTCTACCCTAC-3′) were annealed and inserted into the pGreenPuro vector (System Biosciences, Mountain View, CA).
Cell survival assay
Cells were seeded and cultured in conditioned medium or were treated for 48 h. Cell survival was assessed using a crystal violet staining assay. The cells were washed in phosphate-buffered saline (PBS) and were fixed with 0.1% crystal violet in 10% formaldehyde in PBS for 5 min. The excess crystal violet solution was discarded, and after air-drying completely, the stained cells were lysed with a 2% SDS solution by shaking the plates for 1 h. The optical density was measured at 560 nm using a microplate reader. The percentage absorbance was calculated for each well. The optical density values of cells in the control wells were arbitrarily set to 100% to determine the percentage of viable cells.
Western blot analysis
Whole-cell lysates were subjected to SDS-PAGE, and the proteins were transferred to polyvinylidene difluoride (PVDF) membranes (GE Healthcare UK Ltd, Little Chalfont, UK). After blocking with TBS containing 0.05% Tween-20 and 5% non-fat dry milk for 1 h, the membranes were incubated with primary antibodies overnight. The dilutions for the primary antibodies were 1/2000 for rabbit anti-GS antibody, 1/2000 for anti-ASNS antibody, 1/5000 for anti-LC3B antibody, 1/1000 for anti-ASCT2 antibody 
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Generation of GS-expressing cells and GS-inhibited cells
Flag-tagged empty vector (Vec) or GS vector was transfected into OVC cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions, and the transfected cells were then selected by treatment with G418 (Sigma-Aldrich).
Lentivirus for the transduction of the shRNA vectors was prepared using the pPACK Packaging Kit (System Biosciences, Palo Alto, CA) according to the manufacturer's instructions. The virus titer was measured in infectious units/ml via an RT-PCR-based method using the Global UltraRapid Lentiviral Titer Kit (System Biosciences). KF28 cells were infected with five multiplicity of infection (MOI) of lentivirus with either empty vector (as a control) or the GS-shRNA vector using TransDux (System Biosciences). The selection of infected cells was performed by treatment with 1 µg/ml puromycin (Sigma-Aldrich).
Determination of the sub-G1 cell population by fluorescence-activated cell sorting analysis
Both attached cells and cells floating in the medium were collected, washed in PBS and fixed with 70% cold ethanol on ice for 30 min. Fixed cells were washed in PBS again, and incubated in PBS containing RNase (100 µg/ml) for 30 min at 37°C. Cells were then stained with propidium iodide (Invitrogen), and cell population analysis was performed using the Accuri Ⓡ Flow Cytometer.
Three-dimensional spheroid culture
Ninety-six-well plates were precoated with Matrigel as a basement membrane by adding 75 μl of Matrigel (BD Biosciences, San Jose, CA) to each well and incubating at 37°C for 30 min to allow the Matrigel to solidify. Cells (3.0 × 10 3 per well) that were suspended in standard medium containing 2% Matrigel were then seeded onto the Matrigel-precoated wells. All microscopy images were captured using a Nikon Eclipse E400 (Nikon, Tokyo, Japan), and the spheroid size was measured using ImageJ software (National Institutes of Health, MD). The size relative to the size on the third day was calculated.
In vivo tumor growth assay
Seven-week-old female BALB/c nude mice were purchased from the Charles River Laboratories Japan (Yokohama, Japan). A laparotomy with a transverse incision was performed under anesthesia. Cells (1 × 10 7 cells in 100 µl of PBS with 50% Matrigel) were injected subcutaneously into the flank of the nude mice. ES-2 cells (1 × 10 7 cells in 200 µl of PBS) were injected into the intraperitoneal cavity of the nude mice.
Immunohistochemical analysis
We constructed tissue microarrays from tissue blocks prepared from 316 OVC tumors using a Tissue Microarrayer (Beecher Instruments, Silver Spring, MD) as previously described (18) . Immunohistochemistry was performed on tissue microarray sections. The sections were deparaffinized in xylene and were rehydrated using a graded ethanol series (100, 90, 80, 70 and 50%) to water. After the retrieval of antigens by boiling in 10 mM citrate buffer (pH 6.0), the sections were treated with 0.3% hydrogen peroxide in methanol to inactivate endogenous peroxidase. Nonspecific binding was blocked by incubating in goat serum in PBS. Next, the slides were incubated with rabbit anti-GS antibodies (dilution for both: 1/2000) overnight at room temperature. The bound antibody was visualized using diaminobenzidine as a chromogen (VECTASTAIN Elite ABC kit, Vector Laboratories, Burlingame, CA), and the sections were lightly counterstained with hematoxylin.
The immunohistochemical evaluation was performed by three researchers (A.F., Ju.I. and H.T.) according to our previous studies (18) . Briefly, the intensity score for cytoplasmic GS expression was determined using the Histo-score (H-score), which was calculated by the semiquantitative assessment of both the intensity of staining (graded as follows: 0, nonstaining; 1+, weak; 2+, medium; 3+, strong) and the percentage of positive cells. The formula was (3 × the percentage of cells positive for 3+ staining) + (2 × the percentage of cells positive for 2+ staining) + (1 × the percentage of cells positive for 1+ staining), yielding a range of 0-300 (19) . The expression level of each component was categorized as low or high according to the median H-score value.
Measurement of the Gln level in medium
The Gln level in the medium was measured using the Glutamine Assay Kit (ab19701, Abcam, Cambridge, UK).
Statistical analysis
The correlation between GS expression in primary OVCs and the clinicopathological variables were analyzed using the chi-squared test or Fisher's exact test. For in vitro assays, differences in the population mean between the control and test groups were compared using Student's t-test. Differences with P values lower than 0.05 were considered to be statistically significant.
Results
Differential AA requirements for cell survival in a panel of 14 OVC cell lines
To determine the requirement of each AA for cell survival in 14 OVC cell lines, we examined the sensitivity to culturing in conditioned medium in which the corresponding single AA was depleted ( Figure 1A ). Since EAAs cannot be endogenously synthesized due to the absence of each of the corresponding biosynthetic enzymes, the uptake of extracellular EAAs is critical for cell survival (3) (4) (5) (6) 20) . Nevertheless, in 9 (KK, OVCAR-5, OVCAR-8, SK-OV-3, RMG-1, A#39, SNU119, CaOV3 and MH) of the 14 OVC cell lines, the depletion of any EAA did not affect cell survival, suggesting that these cell lines may be metabolically reprogrammed to survive even under an EAA-depleted condition. However, while NEAAs can be endogenously produced by biosynthetic enzymes (7), we found that the depletion of some NEAAs, either arginine, asparagine, Gln, glycine, proline, serine or tyrosine, had an effect on cell survival in 10 of the OVC cell lines but not the A#39, SNU119, CaOV3 or MH cells. This result suggests that the affected OVC cells may depend on the uptake of the respective extracellular NEAA for cell survival due to the lack of a corresponding synthetase. Therefore, these findings suggest that there may be a cell-type-dependent AA requirement for cell survival in OVC cells.
Effect of GS expression on cell survival under Glndepleted conditions
While it is believed that almost all cancer cells depend on Gln for cell survival or proliferation, the so-called Gln addiction (21), we found that Gln depletion did not affect 8 of the 14 OVC cell lines ( Figure 1A) . Therefore, we hypothesized that the expression of GS, which catalyzes the production of endogenous Gln from Glu, may be involved in the sensitivity to Gln depletion ( Figure 1B) . As a result, we showed a positive correlation between the cell survival rate under a condition of Gln depletion and the expression level of the GS protein in 14 cell lines (P = 0.048, R 2 = 0.28; Figure 1C and D), suggesting that a decrease in the GS protein level may lead to OVC cell dependence on extracellular Gln. Indeed, when FLAG-tagged GS protein was stably expressed in the GS low -OVC cells, OVCAR-3 or OVCAR-8 cells, the cell survival rate of each cell line under Gln depletion was remarkably increased ( Figure 1E ). By contrast, shRNA-or siRNA-mediated inhibition of GS expression in the GS high -OVC cells, KF28 cells, resulted in a decrease in the cell survival rate under conditions of Gln depletion ( Figure 1F ). In addition, the inhibition of Gln uptake by the knockdown of ASCT2, a Gln transporter, was effective in the GS low -OVC cells (P = 0.01 for OVCAR-3 cells) but not in the GS high -OVC cells (P = 0.29 for KF28 cells; Figure 1G ). Taken together, these results suggest that GS expression is critical regarding the requirement of extracellular Gln for OVC cell survival.
Downregulation of GS expression in primary OVC samples
We examined the expression status of the GS protein via immunohistochemical analysis in 316 primary OVC samples. The expression of the GS protein was assessed using the H-score based on the staining intensity and percentage of positive cells (see the Materials and methods). The H-score in normal fimbria of the fallopian tube was 200, and cases with an H-score less than depleted conditions are indicated. Bar, SD. *P < 0.05 and **P < 0.01. (F) Effect of GS knockdown on the cell survival rate under Gln-depleted conditions. GS expression was inhibited by shRNA or siRNA in the negative control (NC) or GS in the high-GS-expressing KF28 cells. Upper and Lower panels are presented as described in (E). *P < 0.05 and **P < 0.01. (G) Effect of ASCT2 knockdown on the cell survival rate under the standard condition. ASCT2 expression was inhibited by siRNA for the negative control (NC) or ASCT2 in the low-GS-expressing OVCAR-3 (left panel) or high-GS-expressing KF28 cells (right panel). The Upper and Lower panels are presented as described in (E). **P < 0.05. 100 were defined as having 'downregulation,' as shown by the immunostaining of serous carcinoma for case 1 (Figure 2A) . We showed that the expression of the GS protein was downregulated in 12 of 131 serous carcinoma cases (9.2%; Figure 2B ). The downregulation of GS was shown in 28 of 87 cases (32.1%) of clear cell carcinoma, in 3 of 44 cases (6.8%) of endometrioid carcinoma, and in 2 of 54 cases (3.7%) of mucinous carcinoma (Table 1 ). In total, GS expression was downregulated in 45 of all 316 cases of OVC tumors (14.2%). However, there was no significant association between any clinical implications and GS expression status.
Effect of GS expression on the sensitivity to treatment with l-asp
We hypothesized that the depletion of extracellular Gln may affect cell growth inhibition in OVC cells together with the downregulation of GS expression. l-asp, one of the most important drugs used for ALL therapy, is an enzyme that catalyzes the hydrolysis of asparagine or Gln to aspartate or Glu, respectively ( Figure 3A) . In the present study, we confirmed that treatment with l-asp induced the complete depletion of Gln in the culture media ( Figure 3B ). We next examined the cell sensitivity to l-asp treatment in the 14 OVC cell lines and found a positive, but not statistically significant, correlation between the expression level of the GS protein and the cell survival rate with l-asp treatment of the 14 OVC cell lines (P = 0.89, R 2 = 0.12; Figure 3C ). As shown in Figure 1A , asparagine depletion of the medium did not affect the survival of the OVC cells, suggesting that the l-asp-induced cytotoxicity is attributed to Gln depletion. Furthermore, the cell survival rate with l-asp treatment was significantly increased in the OVCAR-3 or OVCAR-8 cells that stably expressed GS and was Figure 3D ). We also showed that apoptotic cell death induced by l-asp treatment was remarkably inhibited in the OVCAR-3 cells that stably expressed GS, compared with that in the control-vector cells (13.4% in control-vector cells, 5.0% in GS-expressing cells, P = 0.009; Supplementary  Figure 1 , available at Carcinogenesis Online). We previously demonstrated that autophagy serves a cytoprotective function in l-asp-treated ALL cells (22) ; therefore, we next attempted to define the effect of autophagy activity on the sensitivity of OVC cells to treatment with l-asp. The autophagy flux in three OVC cell lines, two l-asp-sensitive cell lines (OVCAR-3 and OVCAR-8 cells) and one l-asp-resistant cell line (KF28 cells) was evaluated by detecting LC3B form-II (LC3B-II), an autophagosome marker, via western blot analysis. LC3B-II levels were increased by l-asp treatment, and this increase was enhanced by inhibiting autophagosome turnover via the addition of a lysosome inhibitor, bafilomycin A1 (Baf), indicating that treatment with l-asp can induce autophagy equivalently in both l-asp-sensitive and insensitive cells ( Figure 3E) . Similarly, the induction of autophagy was also shown in both control-vector (sensitive) and GSexpressing (resistant) OVCAR-3 cells ( Figure 3F ). These findings exclude the possibility that the induction of autophagy is a determinant for the differential sensitivity to l-asp in OVC cells. Taken together, the depletion of Gln using l-asp may be therapeutically useful strategy for OVCs with downregulation of GS expression. OVC cells. Cells were treated with l-asp (10 U/ml) and/or bafilomycin A1 (Baf.A1, 100 nM) for 2 days. Cell lysates were subjected to SDS-PAGE and were then incubated with the indicated antibodies. The arrow indicates the band for LC3B form-II, an autophagosome marker.
Effect of GS expression on tumor growth in vitro and in vivo
Finally, we found that re-expression of GS induced the inhibition of cell growth under 2D culture or three-dimensional (3D) spheroid culture with standard medium in GS low -OVCAR-3 cells ( Figure 4A ). This GS-mediated growth inhibition was also shown under the hypoxic condition ( Figure 4B ). Furthermore, an in vivo tumor growth assay with tumors formed by the injection of OVC cells into the subcutaneous space of nude mice revealed that the reexpression of the GS protein inhibited tumor growth by OVCAR-3 and OVCAR-8 cells (Figure 4C and D) . In addition, in the peritoneal dissemination model using ES-2 cells, derived from an ovarian clear cell carcinoma, dissemination was frequently observed in the peritoneal cavity with the control-vector cells, whereas none was observed with the ES-2 cells that stably expressed GS ( Figure 4E ). These findings suggest that the downregulation of GS expression may be associated with tumorigenesis in OVC.
Discussion
Gln is a resource for the synthesis of many AAs, proteins, nucleotides and other biologically important molecules and provides nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH) to maintain redox homeostasis (23) (24) (25) . Thus, Gln plays a critical role in cell growth and cell survival. Because many cancer cell lines cannot survive without an exogenous supply of Gln, it has been believed that these cells are dependent on the uptake of extracellular Gln, even though Gln is an NEAA that can be synthesized endogenously (23) . However, in this study, we showed that the depletion of extracellular Gln is effective for cell growth suppression in GS low -OVC cells but not in GS high -OVC cells. Others have previously reported on the GS dependency of the sensitivity to Gln depletion of cell lines from glioblastoma and breast cancer (26, 27 ). Thus, the Gln level endogenously produced by GS is sufficient as a biological resource for GS high -OVC cells to survive despite the depletion of extracellular Gln.
It has been reported that GS is highly expressed in human cancers, including hepatocellular carcinoma, glioblastoma and breast cancer, and can support the cell survival and proliferation of those types of cancer cells (27) (28) (29) (30) . Conversely, we showed that the expression of the GS protein was downregulated in a subset of primary OVC tumors. Notably, the re-expression of GS in GS low -OVC cells can inhibit tumor growth in vitro and in vivo. However, the detailed molecular mechanism of this phenomenon currently remains unknown. Gln can support the survival and growth of cancer cells not only by the synthesis of nucleotides and proteins but also by the production of energy from tricarboxylic acid (TCA) cycle metabolites via the conversion to Glu and α-ketoglutarate through the activity of multiple enzymes (glutaminolysis) (23) . Therefore, we consider that the impaired production of endogenous Gln by low expression of GS may contribute to tumorigenesis by activating the extracellular Gln-mediated glutaminolysis for cell survival and cell growth as shown in Figure 5 . The re-expression of GS into the GS low -OVC cells may lead to metabolic restoration accompanied by reduced glutaminolysis, resulting in the reduction of activity for cell growth under the standard cell culture condition in vitro and tumor growth in vivo. Further investigation, including assessing the change in the number of metabolic intermediates with the re-expression of GS, will be required to define the biological significance of the downregulation of GS expression for the cell growth and survival of OVC cells.
Our data revealed that inhibiting the uptake or decreasing the amount of extracellular Gln may be a therapeutically useful strategy for patients with GS low -OVC cells ( Figure 5 ). Treatment with l-asp is a physiologically safe strategy to induce the enzymatic lowering of extracellular Gln because this enzyme can catalyze the hydrolysis not only of asparagine to aspartate but also of Gln to Glu. We demonstrated that treatment with l-asp was more effective in the GS low -OVC cells than in the GS high -OVC cells. Consistently, the inhibition of GS function by treatment with methionine-l-sulfoximine, which is known as a GS inhibitor, has enhanced l-asp-induced cytotoxicity in hepatocellular carcinoma cells (31) . An alternative agent that could be used to deplete plasma Gln is phenylbutyrate, an FDA-approved pharmacologic for the treatment of hyperammonemia in patients with congenital urea cycle disorders (32) . Pharmacologic doses of phenylbutyrate lead to a significant depletion of plasma Gln levels by conjugating with Gln via Gln-acyltransferase to yield phenylacetylglutamine (33, 34) . Furthermore, in our study, the siRNA-mediated inhibition of a Gln transporter, ASCT2, was more effective in the GS low -OVC cells than in the GS high -OVC cells; therefore, suppressing Gln uptake may be therapeutically applicable for GS low -OVC cells (29, 35, 36) . Indeed, l-γ-glutamyl-pnitroanilide (GPNA), one of a panel of ASCT2 inhibitors, has been reported to inhibit Gln uptake and inhibit the growth of cancer cells (37, 38) . Taken together, our findings that the depletion of extracellular Gln is effective in GS low -OVC cells provide novel insights into the development of precision cancer therapy for OVC based on GS expression.
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